Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	549.85	743.29	594.35	391.57	549.91	285.12
Short-Term Investments	-	-	-	-	-	231.45
Cash & Short-Term Investments	549.85	743.29	594.35	391.57	549.91	516.56
Cash Growth	-16.67%	25.06%	51.79%	-28.79%	6.46%	97.07%
Accounts Receivable	-	-	-	-	-	0.03
Other Receivables	34.07	24.65	49.17	3.09	2.75	9.06
Receivables	34.07	24.65	49.17	3.09	2.75	9.09
Prepaid Expenses	2.88	11.74	29.6	-	-	-
Restricted Cash	6.66	4.59	3.05	3.23	1.28	1.55
Other Current Assets	22.56	28.57	38.11	40.25	15.87	7.51
Total Current Assets	616.02	812.85	714.27	438.14	569.81	534.72
Property, Plant & Equipment	152.7	169.48	233.21	120.17	121.45	64.73
Long-Term Investments	-	4.4	-	-	-	-
Goodwill	160.71	162.16	148.87	52.06	0.8	0.8
Other Intangible Assets	273.68	309.9	335.86	36.44	1.31	1.39
Long-Term Deferred Tax Assets	0.96	0.96	1.93	-	-	-
Other Long-Term Assets	17.65	14.39	14.45	6.89	7.92	8.72
Total Assets	1,222	1,474	1,449	653.7	701.29	610.35

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	16.38	18.12	21.61	3.95	4.59	2.82
Accrued Expenses	66.65	69.53	80.28	41.76	30.29	27.67
Current Portion of Long-Term Debt	-	0.12	0.11	0.04	0.1	0.09
Current Portion of Leases	12.26	21.63	22.11	6.12	5.95	-
Current Unearned Revenue	15.81	37.61	61.77	36.43	56.73	10
Other Current Liabilities	-	0.7	1.59	4.87	2.62	6.08
Total Current Liabilities	122.92	147.71	187.47	93.17	100.27	46.66
Long-Term Debt	0.09	0.19	0.68	1.1	0.54	0.63
Long-Term Leases	50.54	56.02	85.59	43.41	44.42	-
Long-Term Unearned Revenue	120.02	114.01	118.77	51.24	70.26	6.67
Long-Term Deferred Tax Liabilities	18.37	23.26	16.58	1.34	-	-
Other Long-Term Liabilities	3.96	2.08	4.73	-	-	13.45
Total Liabilities	315.9	343.27	413.82	190.26	215.48	67.41

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	3,320	3,170	2,474	1,431	1,125	943.14
Retained Earnings	-2,444	-2,076	-1,431	-967.62	-639.56	-400.08
Comprehensive Income & Other	29.63	36.72	-7.64	-	-	-0.13
Total Common Equity	905.81	1,131	1,035	463.44	485.81	542.94
Shareholders' Equity	905.81	1,131	1,035	463.44	485.81	542.94
Total Liabilities & Equity	1,222	1,474	1,449	653.7	701.29	610.35

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	74.7	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	475.15	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	-17.72%	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	0.89	1.49	1.77	1.64	2.84	4.12
Filing Date Shares Outstanding	543	527.4	401.99	234.65	191.23	170.77
Total Common Shares Outstanding	543	528.18	396.8	234.27	191.02	170.27
Working Capital	493.1	665.14	526.8	344.97	469.55	488.06
Book Value Per Share	1.67	2.14	2.61	1.98	2.54	3.19
Tangible Book Value	471.43	658.8	550.05	374.94	483.7	540.75
Tangible Book Value Per Share	0.87	1.25	1.39	1.60	2.53	3.18
Machinery	-	121.86	128.29	82.22	67.69	53.08
Construction In Progress	-	0.51	2.71	3.23	8.75	16.45
Leasehold Improvements	-	70.78	72.73	45.93	41.87	13.94

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error